The Phase 3 failure removes a major catalyst and likely reduces the probability of success for OCS-01 in DME to near zero. Monitor upcoming Privosegtor PIONEER data and Licaminlimab PREDICT-1 results for pipeline revaluation. The $278M cash runway provides a buffer but the stock may re-rate downward given the setback.
Price Chart
Executive Summary
Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema (DME) failed to meet the primary endpoint of BCVA improvement at Week 52. The company will not pursue an FDA filing for OCS-01 in DME and is refocusing resources on its Privosegtor and Licaminlimab programs. With $278M cash runway into 2H 2029, the financial position is strong but the pipeline setback is material.
Key Facts
- Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in DME failed to meet primary endpoint of BCVA improvement at Week 52
- Secondary endpoint of retinal thickness showed substantial and persistent reduction with OCS-01 vs vehicle in both trials
- Key secondary endpoint of ≥15-letter BCVA gain was not met in both trials
- Oculis will not pursue FDA regulatory filing for OCS-01 in DME at this time
- Company refocusing on Privosegtor PIONEER registrational program in optic neuropathies and Licaminlimab PREDICT-1 trial in dry eye disease
- Cash position of $278M as of March 31, 2026, providing runway into 2H 2029
Financial Impact
OCS-01 was a key pipeline asset; failure eliminates a potential revenue stream. No specific R&D spend or market size disclosed for DME indication. Cash runway unaffected near-term.
Risk Factors
- Further negative read-through from DIAMOND data analysis
- Privosegtor or Licaminlimab trials may also face setbacks
- Potential dilution if cash runway needs extension
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303787 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $8.03 (−8.33%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $8.03 (−37.07%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $8.03 (−37.07%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $8.03 (−27.00%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $8.03 (−26.87%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $8.03 (+64.63%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $8.03 (−73.59%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $8.03 (−73.59%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $8.03 (−74.17%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $8.03 (−71.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers